AI in Healthcare Innovation

Navigating AI Use Cases in Healthcare: From Hype to Evidence! I’ve mapped the rapidly expanding universe of AI use cases in healthcare from early-stage “on the horizon” innovations to “safe bets” that are already backed by strong evidence. I analyzed them on two scales, little evidence to evidence-based; and low risk to high risk. This yielded four groups: 1) Speculative and risky (little evidence, high risk) 2) On the horizon (little evidence, low risk) 3) Handle with care (evidence-based, high risk) 4) Safe bet (evidence-based, low risk) I hope this infographic helps clarify the path ahead: which solutions demand more research and caution (autonomous AI prescribing, mental health chatbots), and which are ready for prime time (AI-powered clinical documentation, radiology analysis, ECG interpretation). I'm curious to hear what you see significantly differently! #DigitalHealth #HealthTech #AI #Future #HealthcareInnovation

Today in Cell, we published new research showing how AI can help accelerate cancer discovery. With GigaTIME, we can now simulate spatial proteomics from routine pathology slides, enabling population-scale analysis of tumor microenvironments across dozens of cancer types and hundreds of subtypes.   Developed in partnership with Providence and the University of Washington, our hope is that this work helps scientists move faster from data to insight, revealing new links between genetic mutations, immune activity, and clinical outcomes, and ultimately improving health for people everywhere. https://lnkd.in/dSpPdtzz

Right now, every CEO is wondering the same thing: “How can artificial intelligence help maximize our impact?”   Delivering on the promise of AI isn’t just good business, it has the potential to help us address some of society’s most pressing challenges. So today, I wanted to offer a closer look at how AI is helping us discover new medicines at Novartis.   The process of identifying a new drug, running patient clinical trials, and bringing it to market takes over a decade. Each new medicine costs on average $2 billion to develop, and we know nearly 9 in 10 of the treatments we work on will fail before they ever reach patients.   A major early step in that process is identifying individual targets in the body that we want to design a drug for. Once we identify that target, which most commonly is a protein, we look for molecules that might address the target’s underlying issue – ultimately those molecule structures form the basis for every successful treatment.   Unlocking the right protein and molecular structures is complex stuff – each step often takes years to get right and our scientists consider billions of potential chemical structures that might lead to effective and safe drug candidates.   AI offers us the chance to accelerate that process. Working with partners at Isomorphic Labs – including members of the Google DeepMind team that were awarded the Nobel Prize this year – we’re now able to do things like model how a protein folds and interacts with the molecules we design. AI models also make it possible for us to analyze different chemical structures simultaneously. It has the potential to add up to significant time savings for our drug development scientists and their work to predict what molecules might treat specific diseases better and faster.   We’re just at the beginning of what this technology can do. As we incorporate AI throughout Novartis’ work, I’m excited to see all the ways it helps us unlock the mysteries of human biology, so we can deliver better medicines that improve and extend patients’ lives.

🚨 AI JUST HIT ROCHE’S EARNINGS CALL 🚨 Roche’s Q3 2025 earnings call quietly revealed something bigger than a quarterly update — it showed where diagnostics is heading. They announced the Kidney Klinrisk Algorithm — an AI-driven risk stratification tool that just received its CE mark in Europe. This isn’t just a new test. It’s the start of a new category of diagnostics — where routine lab results, imaging, and patient data combine to predict risk before symptoms even appear. “By combining AI with routine tests, Roche helps physicians identify patients at risk of kidney function decline early on, enabling more informed and confident decision-making.” 💡 The signal beneath the noise: ✅ AI + Multi-Modal Data — Fusing clinical, biomarker, imaging, and real-world evidence to find patterns humans can’t see. ✅ Biomarker-Driven Precision — Identifying patient subgroups that respond differently, turning reactive testing into proactive insight. ✅ Data Governance & Traceability — Building regulated, audit-ready data environments to support CE-marked and FDA-cleared algorithms. ✅ Speed to Insight — Automating model development pipelines so clinicians don’t wait months for answers that data could reveal in days. For an industry where Diagnostics has been the slowest to digitize, this marks a real inflection point: from test results ➜ to algorithms ➜ to earlier, smarter interventions. Roche may have lit the spark — but the opportunity runs across the entire ecosystem. The companies who can unify multi-omics, imaging, and clinical data under a compliant, AI-ready framework will define the next era of precision medicine.

This paper explores how AI is shifting from a promising concept to practical application in clinical medicine, highlighting its transformative potential, existing limitations, and future needs. 1️⃣ AI now rivals expert clinicians in diagnostic tasks—deep convolutional neural networks match dermatologists in classifying skin lesions, and ML improves cancer prognosis prediction accuracy. 2️⃣ LLMs like ChatGPT support emergency care decisions, generate clinical notes, and aid surgical workflows with up to 90% instrument recognition accuracy. 3️⃣ AI enhances operational efficiency by automating documentation, enabling real-time translation, and optimizing EHR management through autoML. 4️⃣ Core limitations include lack of transparency ("black box" AI), bias in training data, poor generalizability, usability gaps in clinical settings, and weak regulatory oversight. 5️⃣ Ethical concerns focus on accountability, clinician overreliance, patient privacy, and informed consent in data use, especially affecting marginalized groups. 6️⃣ Explainable AI (XAI) is essential to gain clinician trust—tools must align with clinical reasoning, not just technical transparency. 7️⃣ Bias mitigation requires more than diverse datasets; adaptive learning and real-time fairness audits are needed for equitable outcomes. 8️⃣ Real-world adoption challenges persist—future studies must evaluate AI’s impact on workload, decision-making, and patient outcomes in dynamic settings. 9️⃣ Regulatory evolution is critical—unlike drugs, AI tools often bypass RCTs. Continuous post-deployment monitoring is needed to ensure safety and accountability. 🔟 The paper calls for interdisciplinary collaboration and deliberate implementation strategies to ensure AI enhances care rather than widens healthcare inequities. ✍🏻 Ariana Genovese, Sahar Borna, Cesar Abraham Gomez Cabello, MD, Syed Ali Haider, Prabha Srinivasagam, Maissa Trabilsy, Antonio Jorge de Vasconcelos Forte. From Promise to Practice: Harnessing AI’s Power to Transform Medicine. Journal of Clinical Medicine. 2025. DOI: 10.3390/jcm14041225 ✅ Sign up for our newsletter to stay updated on the most fascinating studies related to digital health and innovation: https://lnkd.in/eR7qichj

AI Skeptic: "Randomized Clinical Trials for AI are too difficult to implement." Sweden: "Here’s a large-scale RCT with 105,934 participants, testing AI in real-world clinical practice within a national screening program" The MASAI trial, a randomized, controlled, non-inferiority study, tested AI-supported mammography screening against standard double reading in Sweden’s national screening program. Published in The Lancet Digital Health, it provides real-world evidence on AI’s impact in clinical practice. Key results: ✔️ 29% increase in cancer detection (6.4 vs. 5.0 per 1,000 screened participants, p=0.0021) ✔️ 44% reduction in screen-reading workload (61,248 vs. 109,692 total readings) ✔️ No significant rise in false positives (1.5% vs. 1.4%, p=0.92) Importantly, AI did not just detect more cancers—it detected more clinically relevant ones: 🔹 More small, lymph-node negative invasive cancers (270 vs. 217) 🔹 Increased detection of aggressive subtypes, including triple-negative and HER2-positive cancers 🔹 No increase in low-grade ductal carcinoma in situ, reducing concerns about overdiagnosis This trial is a landmark in demonstrating that AI in medicine can and should be tested under the same rigorous standards as new drugs and medical devices. When the stakes are high, clinical evidence—not hype—should drive adoption! Source: https://lnkd.in/d8s5NM9W

Earlier this year, a close family member was dangerously ill in India. The diagnosis wasn’t working. The symptoms were escalating. No one knew why. We felt that familiar dread - being far from the situation, and even farther from certainty. So I did what millions of people now do in moments of uncertainty: I asked ChatGPT. Typed in the symptoms, context, and history - not expecting magic, just hoping for perspective. What came back was startlingly precise: It could be this. If so, check the kidneys. If the kidneys are involved, watch for infection. If it’s in the blood, it could be sepsis. Escalate - fast. It was right. All of it. We flagged it to the doctors. It shaped the next set of tests. And it helped turn a very bad situation around- fast. That moment crystallized something for me: AI isn’t about replacing doctors. It’s about replacing helplessness. There’s a lot of talk in Silicon Valley about curing death. Like, literally - curing aging, reversing entropy, building new bodies from cells that forgot they were old. Some of it will work. Much of it will take decades. But the more immediate, life-changing breakthroughs are already happening - not at the edge of life, but at the frontlines of medicine. Just this week: ▪️Microsoft AI Diagnostic Orchestrator (MAI‑DxO) outperformed experienced physicians. It was tested on 304 real-world case studies published in The New England Journal of Medicine. MAI-DxO solved 85.5% of them. By comparison, 21 experienced physicians solved just 20%. How? By mimicking a panel of clinical minds: One AI model orders tests, another evaluates the results, others debate, reframe, escalate. It’s a structured, chain-of-thought system modeled on real diagnostic reasoning. And it recommended fewer unnecessary tests, saving both time and cost. Yes, it’s early. It hasn’t been deployed in hospitals. But the signal is loud: we’re not far from AI-powered co-pilots for frontline care. ▪️ Google DeepMind's AlphaGenome, tackled a different frontier: the "dark matter" of DNA. Most disease-causing mutations don’t lie in genes, they hide in the regulatory code. Until now, we couldn’t see them at scale. AlphaGenome can process 1m base pairs at once - entire genomic neighborhoods. It’s already predicted how some non-coding mutations can trigger cancer. And it trained in just four hours. If MAI‑DxO gives us a better map of what’s happening now, AlphaGenome gives us a telescope into what might happen next. These tools don’t just answer questions. They reshape who gets to ask them. This is what makes the AI revolution in medicine so powerful. Not just that it might one day extend life. But that it already extends understanding. That it makes complexity legible. That it turns patients into partners - and doctors into augmented super-thinkers. And that alone could save millions of lives.

AI’s impact on medicine is no longer theoretical—it’s redefining daily clinical practice, medical research, and the very fabric of physician training. Breakthroughs like Google DeepMind’s AlphaFold2 have let researchers predict the structure of nearly every known protein, accelerating new drug development and igniting a wave of biotech innovation. AI models are now outperforming traditional methods—detecting cancer, forecasting disease progression, and driving efficiencies in active compound discovery. On the operational side, hospitals are leveraging large language models to automate clinical documentation and summarize complex records. The result: clinicians spend less time on paperwork—and more time with patients—helping combat burnout and improve satisfaction for both sides. Medical education is also evolving. Universities such as Stanford and Mount Sinai are weaving AI training into their curricula, recognizing that tomorrow’s doctors need to not only master clinical knowledge but also the critical thinking to collaborate with AI tools effectively. Simulated surgical training, AI-powered feedback, and new pharmacy protocols show that the skillset for modern medicine is expanding—and institutions are responding accordingly. Caution is warranted: Algorithmic bias, data privacy, and the need for robust validation remain real concerns. Yet the pace of deployment and the scope of benefit make clear that AI is not a distant disruptor; it’s a core enabler of the industry’s future. Now is the time for healthcare leaders, educators, and innovators to shape policies, invest in talent, and reimagine workflows. Let’s ensure that AI’s integration into medicine truly elevates care, training, and research for all. https://lnkd.in/gwi3htAJ #AIinMedicine #HealthcareInnovation #MedicalResearch #ClinicalAI #HealthTech #AIEducation #FutureOfMedicine #DigitalHealth #MedTech #HealthcareLeadership

AI in healthcare is not simply another technology upgrade. It is a matter of trust, safety, and ultimately, human life. In many sectors, an AI error might lead to inconvenience or financial loss. In healthcare, an AI error can mean a missed diagnosis, an inappropriate treatment pathway, or avoidable harm. That is why AI adoption in healthcare must be held to a higher standard than in almost any other industry. It requires deeper validation, stricter governance, and human guardrails at every stage. A framework I find particularly helpful is 𝐀𝐈 + 𝐑𝐀𝐂𝐓⁣, strengthened through a Human-Centred AI lens. 𝐑 = 𝐑𝐞𝐚𝐝𝐢𝐧𝐞𝐬𝐬⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣The risk begins long before deployment. If clinical data is incomplete, biased, or unrepresentative, AI systems can fail quietly, often affecting the most vulnerable populations first. Readiness must include: →Data integrity and provenance →Regulatory compliance →Clear clinical problem definition →Ethical and patient safety accountability 𝐀 = 𝐀𝐝𝐨𝐩𝐭𝐢𝐨𝐧⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ ⁣⁣⁣⁣⁣⁣⁣⁣In healthcare, adoption is not about installing a tool, it is about integrating it into clinical judgment. The risk is over-reliance, alert fatigue, or the introduction of friction into already pressured workflows. Human-centred adoption means: →Clinicians remain firmly in the loop →AI outputs are explainable and challengeable →Training supports human-AI collaboration, not replacement 𝐂 = 𝐂𝐚𝐩𝐚𝐛𝐢𝐥𝐢𝐭𝐲⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣Healthcare AI is not static. Models drift, populations change, and clinical practice evolves. The risk is that a system that appears safe today may not remain safe tomorrow. Capability requires: →Continuous monitoring and evaluation →Governance structures spanning clinicians, data, ethics and risk →Ongoing validation, not one-off approval 𝐓 = 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣True transformation is not automation for its own sake. The risk of scaling without safeguards is amplified inequity, diminished patient trust, and decision-making that feels outsourced. Transformation must prioritise: →Better patient outcomes and experience →Equity across communities →Shared decision-making, supported, not replaced, by AI The central truth is this: 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐀𝐈 𝐢𝐬 𝐧𝐨𝐭 𝐜𝐨𝐧𝐬𝐮𝐦𝐞𝐫 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲. 𝐈𝐭 𝐢𝐬 𝐬𝐚𝐟𝐞𝐭𝐲-𝐜𝐫𝐢𝐭𝐢𝐜𝐚𝐥.⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣Progress must be ambitious, but responsibility must be uncompromising. The question is not whether AI will shape the future of care. It is whether we shape it with the rigour, humility, and human focus that patients deserve. What is the single most important gate check you insist on before scaling AI in clinical environments? ♻️ Share if this resonates ➕ Follow (Jyothish Nair) for reflections on AI, change, and human-centred AI #ResponsibleAI #AI #DigitalTransformation #HumanCentredAI

40% more drugs at 60% of the cost - that's what serious investors in pharmaceutical companies believe AI can deliver for our industry. But how do we get there? This week, at our Business Insights & Technology (BI&T) Quarterly Town Hall, we explored three critical questions: What's driving the AI frenzy in life sciences? What have we learned from our own three-year journey? And how must our profession evolve to stay relevant? We broke the conversation into three parts: 1. Why so much energy around AI in life sciences? The transformation is already underway: faster discovery of targets, more efficient clinical trials, higher reliability in manufacturing, and better patient engagement. Analysts forecast that AI could enable 40% more drugs at 60% of the cost - and so while pilots and proof of concepts are useful, they are singles and doubles in a game where home runs are expected 2. What actually moves the needle - lessons from three years in. Our AI journey has taught us what works: - Layer AI onto reimagined processes, not old ones - Lead with product to build "AI-powered race cars," not faster horses - Connect top-down vision with bottom-up needs - workforce productivity and enterprise transformation will not align spontaneously; we must be a cause in the matter of aligning it - Keep decision-making teams small and focused (see: the Ringelmann effect - too many cooks spoil the broth) 3. Reinventing IT in the age of AI. Every decade, enterprise technology must reinvent itself. This is one of those moments. The shifts ahead include: - From translators → product leaders (as business users gain AI tools to build directly) - From consumers → creators of advantage (extending technology uniquely rather than just buying what's off the shelf) - From fragmented processes run by people → enablers of self-improving processes (AI-native by default) - From change as a project → change as a daily capability For decades, IT organizations had two things: scale and skill. We were an internal monopoly. In the era of vibe coding, this monopoly is coming to an end. We have to lead, not gatekeep. The future won't wait. As AI democratizes technology, IT functions must choose: be reactive and widen the gap, or be proactive and narrow the gap. At BMS, we're committed to the latter by: 1) Equipping our workforce with state-of-the-art AI tools to allow them to self-explore, 2) Empowering and upskilling our workforce through AI literacy programs which tens of thousands of employees have already completed, and 3) Concentrating efforts on functional applications of AI that can make a material difference to the company. We stand at a unique intersection: the opportunity to do the most meaningful work of our careers while defining what the future of our profession will be.